Date: 2014-11-07
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 56th American Society of Hematology (ASH) Annual Meeting held in San Francisco, CA from December 6 to 9
Company: Chugai Pharmaceutical (Japan) Roche (Switzerland)
Product: ACE910 (anti-factor IXa x anti-factor X humanized bispecific antibody)
Action
mechanism: bispecific antibody.
Disease: hemophilia A
Therapeutic area: Hematological diseases - Genetic diseases Rare diseases
Country:
Trial details:
Latest
news: * On November 7, 2014, Chugai Pharmaceutical announced that the Japanese phase I clinical data of anti-factor IXa x anti-factor X humanized bispecific antibody \"ACE910,\" currently being developed for the indication of hemophilia A will be presented at the 56th American Society of Hematology (ASH) Annual Meeting held in San Francisco, CA from December 6 to 9. This phase I trial is conducted with both healthy volunteers and hemophilia A patients. The abstrast is entitled Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study (Abstract 691). The study demonstrates that once-weekly SC ACE910 prophylaxis possesses a favorable safety and a promising efficacy profiles in severe hemophilia A patients irrespective of the presence of FVIII inhibitors. Collectively, ACE910 is expected to offer an effective and convenient prophylactic treatment option for hemophilia A, including patients with FVIII inhibitors and/or with venous access difficulty.Chugai co-develops the compound globally with Roche.
